151 related articles for article (PubMed ID: 22054111)
21. A case of hepatitis B reactivation due to the hepatitis B virus escape mutant in a patient undergoing chemotherapy.
Wu C; Shi H; Wang Y; Lu M; Xu Y; Chen X
Virol Sin; 2012 Dec; 27(6):369-72. PubMed ID: 23180290
[TBL] [Abstract][Full Text] [Related]
22. Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations.
Sucupira MV; Mello FC; Santos EA; Niel C; Rolla VC; Arabe J; Gomes SA
Mem Inst Oswaldo Cruz; 2006 Sep; 101(6):655-60. PubMed ID: 17072479
[TBL] [Abstract][Full Text] [Related]
23. [Investigation of occult hepatitis B in HIV infected patients].
Altınbaş A; Ergünay K; Calık Başaran N; Alp A; Turgut D; Hasçelik G; Uzun Ö; Unal S
Mikrobiyol Bul; 2011 Apr; 45(2):353-8. PubMed ID: 21644079
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.
Wongprasit P; Manosuthi W; Kiertiburanakul S; Sungkanuparph S
AIDS Patient Care STDS; 2010 Apr; 24(4):205-9. PubMed ID: 20377434
[TBL] [Abstract][Full Text] [Related]
25. Occult hepatitis B and HIV infection.
Soriano V; Aguilera A; Gonzalez R; Gomez-Gallego F; Barea L; Treviño M; Corral O
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1403-1407. PubMed ID: 30969194
[TBL] [Abstract][Full Text] [Related]
26. New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.
Dunn D; Price H; Vudriko T; Kityo C; Musoro G; Hakim J; Gilks C; Kaleebu P; Pillay D; Gilson R;
J Acquir Immune Defic Syndr; 2021 Jan; 86(1):98-103. PubMed ID: 33306565
[TBL] [Abstract][Full Text] [Related]
27. HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
Belyhun Y; Maier M; Liebert UG
Antivir Ther; 2017; 22(2):97-111. PubMed ID: 27354181
[TBL] [Abstract][Full Text] [Related]
28. Antiviral treatment for human immunodeficiency virus patients co-infected with hepatitis B virus: combined effect for both infections, an obtainable goal?
Wolters LM; Niesters HG; de Man RA; Schalm SW
Antiviral Res; 1999 May; 42(1):71-6. PubMed ID: 10333144
[TBL] [Abstract][Full Text] [Related]
29. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Núñez M; Ramos B; Díaz-Pollán B; Camino N; Martín-Carbonero L; Barreiro P; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2006 Sep; 22(9):842-8. PubMed ID: 16989608
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ;
J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786
[TBL] [Abstract][Full Text] [Related]
31. Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans.
Lukhwareni A; Gededzha MP; Amponsah-Dacosta E; Blackard JT; Burnett RJ; Selabe SG; Kyaw T; Mphahlele MJ
Viruses; 2020 Jun; 12(6):. PubMed ID: 32545313
[TBL] [Abstract][Full Text] [Related]
32. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.
Talotta R; Atzeni F; Sarzi Puttini P
BMC Pharmacol Toxicol; 2016 Apr; 17():17. PubMed ID: 27098382
[TBL] [Abstract][Full Text] [Related]
33. Longitudinal evaluation of occult hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption.
Bagaglio S; Bianchi G; Danise A; Porrino L; Uberti-Foppa C; Lazzarin A; Castagna A; Morsica G
Infection; 2011 Apr; 39(2):121-6. PubMed ID: 21424854
[TBL] [Abstract][Full Text] [Related]
34. Occult hepatitis B virus infection and S gene escape mutants in HIV-infected patients after hepatitis B virus vaccination.
Aghakhani A; Mohraz M; Aghasadeghi MR; Banifazl M; Vahabpour R; Karami A; Foroughi M; Ramezani A
Int J STD AIDS; 2016 Oct; 27(11):967-72. PubMed ID: 26384943
[TBL] [Abstract][Full Text] [Related]
35. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
[TBL] [Abstract][Full Text] [Related]
36. HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing.
Audsley J; Littlejohn M; Yuen L; Sasadeusz J; Ayres A; Desmond C; Spelman T; Lau G; Matthews GV; Avihingsanon A; Seaberg E; Philp F; Saulynas M; Ruxrungtham K; Dore GJ; Locarnini SA; Thio CL; Lewin SR; Revill PA
Virology; 2010 Sep; 405(2):539-47. PubMed ID: 20655563
[TBL] [Abstract][Full Text] [Related]
37. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
Cohen Stuart JW; Velema M; Schuurman R; Boucher CA; Hoepelman AI
J Med Virol; 2009 Mar; 81(3):441-5. PubMed ID: 19152397
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence.
Bivigou-Mboumba B; Amougou-Atsama M; Zoa-Assoumou S; M'boyis Kamdem H; Nzengui-Nzengui GF; Ndojyi-Mbiguino A; Njouom R; François-Souquière S
PLoS One; 2018; 13(1):e0190592. PubMed ID: 29315352
[TBL] [Abstract][Full Text] [Related]
39. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
Boyd A; Moh R; Gabillard D; le Carrou J; Danel C; Anglaret X; Eholié SP; Maylin S; Delaugerre C; Zoulim F; Girard PM; Lacombe K;
Antivir Ther; 2015; 20(6):643-54. PubMed ID: 25852125
[TBL] [Abstract][Full Text] [Related]
40. Characterization of occult hepatitis B virus infection among HIV positive patients in Cameroon.
Gachara G; Magoro T; Mavhandu L; Lum E; Kimbi HK; Ndip RN; Bessong PO
AIDS Res Ther; 2017 Mar; 14(1):11. PubMed ID: 28270215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
